Related references
Note: Only part of the references are listed.Programmed death receptor Ligand 1 expression in eyelid sebaceous carcinoma: a consecutive case series of 41 patients
Shiqiong Xu et al.
ACTA OPHTHALMOLOGICA (2019)
Change in Eyelid Carcinoma T Category With Use of the 8th Versus 7th Edition of the American Joint Committee on Cancer: Cancer Staging Manual
Stephanie Ding et al.
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY (2019)
New Insights into the Tumor Microenvironment Utilizing Protein Array Technology
Wei Huang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
Evidio Domingo-Musibay et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma
Thomas J. Kandl et al.
ONCOIMMUNOLOGY (2018)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases
Erna-Elise Paulsen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
Joohee Sul et al.
ONCOLOGIST (2016)
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
Hye Ryun Kim et al.
SCIENTIFIC REPORTS (2016)
PD-L1 Is Frequently Expressed in Acute Myeloid Leukemia Patients with Leukocytosis
Barbora Brodska et al.
BLOOD (2016)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Confusing signals: Recent progress in CTLA-4 biology
Lucy S. K. Walker et al.
TRENDS IN IMMUNOLOGY (2015)
Overcoming tumor-mediated immunosuppression
Hans Anton Schloesser et al.
IMMUNOTHERAPY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
Mario Sznol et al.
CLINICAL CANCER RESEARCH (2013)
Avoidance of exenteration in orbital sebaceous gland carcinoma with neoadjuvant chemotherapy
Ajay Gogia et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2013)
Tumor stroma as targets for cancer therapy
Jing Zhang et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
O. J. Finn
ANNALS OF ONCOLOGY (2012)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia
Miroslaw J. Szczepanski et al.
CLINICAL CANCER RESEARCH (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
Brian T. Fife et al.
IMMUNOLOGICAL REVIEWS (2008)
The tumor microenvironment and its role in promoting tumor growth
T. L. Whiteside
ONCOGENE (2008)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
Sebaceous carcinoma of the ocular region: A review
JA Shields et al.
SURVEY OF OPHTHALMOLOGY (2005)
Sebaceous carcinoma of the eyelids - Personal experience with 60 cases
JA Shields et al.
OPHTHALMOLOGY (2004)
Share Paper
